Topical Lidocaine (5% patch)
Treatment for Peripheral Neuropathy
Typical Dosage: Up to 3 patches for up to 12 hours/day
Effectiveness
60%
Safety Score
85%
Clinical Trials
7
Participants
9K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe
Treatment Details
Dosage Range
Up to 3 patches for up to 12 hours/day
Time to Effect
30 minutes to 2 hours
Treatment Duration
Applied daily as needed
Evidence Quality
MODERATENumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,400
Monitoring:$150
Side Effect Mgmt:$20
Total Annual:$2,570
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$35,000/QALY
QALYs Gained
0.02
Outcome-Based Costs
Cost per Responder
$6,763.16
Cost per Remission
$128,500
Prescription Access Economics
Annual Societal Loss per Patient
$1,247.5
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$375/year
Time Cost
$112.5/year
Travel + wait time
Insurance Admin Cost
$60/year
Prior auth, claims
Rx Price
$2,400/year
Potential OTC Price
$1,200/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWTopical Lidocaine (5% patch) Outcomes
for Peripheral Neuropathy
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+38%
Remission Rate
+2%
Common Side Effects
Application site erythema
+8%
Application site edema
+5%
Application site pruritus
+5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
4 completed trials for Topical Lidocaine (5% patch) in Peripheral Neuropathy
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy
NCT01086150COMPLETEDPHASE2, PHASE3
51 participants
INTERVENTIONAL
Albany, United States
Started: Oct 1, 2009
Symptom Management After Breast Cancer Surgery
NCT00686127COMPLETEDPHASE4
21 participants
INTERVENTIONAL
San Francisco, United States
Started: Sep 1, 2003
Topical Lidocaine: Predictors of Response in Peripheral Nerve Injury
NCT01112748COMPLETEDPHASE4
24 participants
INTERVENTIONAL
Aarhus C, Denmark
Started: Apr 1, 2010
A Mechanistic Evaluation of the Nociceptive Desensitizing Properties of Topical Capsaicin
NCT03587220COMPLETEDNA
44 participants
INTERVENTIONAL
Aalborg, Denmark
Started: Aug 1, 2018